IFNγ Signaling in Tumor-Associated Myeloid Cells Linked to Resistance Against Immune Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

Researchers have identified a key mechanism contributing to resistance against immune checkpoint inhibitors in advanced renal cell carcinoma (RCC). The study, conducted at Dana-Farber Cancer Institute, highlights the role of interferon-gamma (IFNγ) signaling within tumor-associated myeloid cells as a significant factor in limiting the effectiveness of these immunotherapy treatments. Immune checkpoint inhibitors are widely used in cancer therapy to enhance the immune system’s ability to target and destroy tumors.

The findings reveal that IFNγ signaling in myeloid cells within the tumor microenvironment plays a critical role in driving this resistance. Tumor-associated myeloid cells are known to influence immune responses, and their interaction with IFNγ appears to suppress anti-tumor activity, reducing the efficacy of checkpoint inhibitors. This discovery provides insight into how RCC tumors evade immunotherapy and may inform future strategies for overcoming treatment resistance. Researchers suggest further investigation into targeting this pathway as a potential avenue for improving outcomes in patients with advanced kidney cancer.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: October 31, 2025

Related posts:

Aiming for Earlier Intervention, Flagship Startup Etiome Emerges to Define ‘Biostages’ of Disease Medical Device Packaging Design Prioritizes Sterility and Regulatory Compliance PLPC-DB Oncology Immunotherapy Platform Announced by OGRD Alliance with Non-Cellular and Lyophilized Design Study Explores Link Between Peripheral Inflammation and Cognitive Decline in Parkinson’s Disease

Author

GOAI